Clinical Trials In Nashville
Discover hundreds of clinical trials in Nashville.
Search clinical trials in Nashville by condition or phase.
Academic-Community EPINET (AC-EPINET)
Sponsor:
Indiana University
Location:
Code:
NCT04497857
Conditions
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorders
Major Depression with Psychotic Features
Bipolar Disorder with Psychotic Features
Eligibility Criteria
Sex: All
Age: 16 - 35
Healthy Volunteers: Not accepted
Interventions
Coordinated Specialty Care (CSC)
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
Sponsor:
Abramson Cancer Center at Penn Medicine
Location:
Code:
NCT04841148
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
HCQ
Avelumab
Palbociclib
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05754957
Conditions
Acute Coronary Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Milvexian
Placebo
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Sponsor:
Amneal Pharmaceuticals, LLC
Location:
Code:
NCT05401357
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution
Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Sponsor:
Foghorn Therapeutics Inc.
Location:
Code:
NCT04891757
Conditions
Advanced Hematologic Malignancy
Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Relapsed Myelodysplastic Syndromes
Refractory Myelodysplastic Syndromes
Eligibility Criteria
Sex: All
Age: 16+
Healthy Volunteers: Not accepted
Interventions
FHD-286
Low Dose Cytarabine
Decitabine
A Study with NKT3964 for Adults with Advanced/Metastatic Solid Tumors
Sponsor:
NiKang Therapeutics, Inc.
Location:
Code:
NCT06586957
Conditions
Solid Tumor
Advanced Solid Tumor
Solid Tumor, Adult
Metastatic Tumor
Ovarian Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
NKT3964
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Sponsor:
SURGE Therapeutics
Location:
Code:
NCT05710848
Conditions
Non-muscle-invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
STM-416
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
Sponsor:
AbbVie
Location:
Code:
NCT04499248
Conditions
Open-angle Glaucoma
Ocular Hypertension
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AGN-193408 SR
Lumigan
Sham Administration
Lumigan Vehicle